Advertisement

St. Jude Medical touts new findings from its failed RESPECT trial, reporting that the Amplatzer PFO closure device demonstrated benefits over drug therapy alone.

St. Jude Medical logo

Medical device giant St. Jude Medical (NYSE:STJ) resurrected data from its failed RESPECT study, touting additional analyses and benefits of its Amplatzer patent foramen ovale closure device.

St. Jude took a hit last year when the RESPECT trial failed to meet its clinical endpoints, but the company wasn't about to stop there.

Advertisement
Advertisement